Regentatlantic Capital LLC Pds Biotechnology Corp Transaction History

Regentatlantic Capital LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$0.67 - $3.04 $10,554 - $47,889	-15,753 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$2.08 - $4.07 $5,183 - $10,142	-2,492 Reduced 13.66%	15,753 $42,000
Q3 2019 Oct 22, 2019	BUY	$3.38 - $6.71 $61,668 - $122,423	18,245 New	18,245 $62,000

4.05M

253K

70.4K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $42.7M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Regentatlantic Capital LLC with notifications on news.